Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, Chart & Analysis
About Madrigal Pharmaceuticals, Inc. (MDGL)
Healthcare · Biotechnology
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NMS
- CEO
- Mr. William J. Sibold
- Employees
- 915
- IPO year
- 2007
- Market cap
- $10.5B
- Forward P/E
- 47.38
- EPS (TTM)
- $-12.85
- Book value
- $22.68
- 52-week range
- $405 – $615
- Revenue (TTM)
- $1.3B
- Profit margin
- -25.3%
- Return on equity
- -53.3%